Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15908554 | 0.93 | CYP1A2 (0.34) | CNR2TSHRMAPK1CYP1A2CYP3A4 | |
| SCHEMBL15908553 | 0.88 | GRIN2B (0.37) | TSHRMAPK1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15908562 | 0.85 | TSHR (0.36) | CNR2TSHRMAPK1 | |
| SCHEMBL15908533 | 0.84 | CNR2 (0.33) | CNR2TSHRMAPK1 | |
| SCHEMBL15908538 | 0.81 | PDE5A (0.39) | — | |
| SCHEMBL15908539 | 0.81 | SPHK1 (0.35) | CNR2TSHRMAPK1 | |
| SCHEMBL15908537 | 0.79 | SPHK1 (0.34) | CNR2 | |
| SCHEMBL9978103 | 0.78 | CYP3A4 (0.36) | TSHRCYP3A4 | |
| SCHEMBL15553842 | 0.75 | PARG (0.42) | TSHRALDH1A1 | |
| SCHEMBL15908530 | 0.73 | AGTR1 (0.39) | TSHRCYP1A2CYP3A4CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190023692-A1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2019-01-24 | — | — | US | disclosed |
| US-20170260166-A1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ATIVIRAL AGENTS | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-09-14 | — | — | US | disclosed |
| US-20170260166-A1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ATIVIRAL AGENTS | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-09-14 | — | — | US | disclosed |
| EP-2948444-B1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-12-07 | — | — | EP | disclosed |
| WO-2014114776-A1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023692-A1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | SQOR, SDHA, DHX15 | CNR2 4705/4885TSHR 4855/4885MAPK1 2139/4885 |
| US-20170260166-A1 | QUINOXALINONES AND DIHYDROQUINOXALINONES AS RESPIRATORY SYNCYTIAL VIRUS ATIVIRAL AGENTS | ATIC, DHX15, SQOR | CNR2 4692/4885TSHR 4847/4885MAPK1 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.